Ocugen Closes $7.5 Million Series B Financing
Summary
"We are very proud of the progress we have made with our pipeline and steadfast in our plans to advance these products toward commercialization," stated Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-founder of Ocugen. "We are pleased to have closed this round of financing and are appreciative of the confidence shown by our new investors, all of which have proven track records of success in the pharmaceutical industry." The Companys drug candidates are focused on activating novel biologic pathways to treat inflammatory, degenerative, and neovascular diseases of the eye and are designed to deliver value over the near, mid and long-term. "Ocugen continues to demonstrate a readiness for growth and steady progress toward its plans for commercialization," stated Mr. Nezih Barut, Chairman of Abdi Ibrahim. "Since its inception, Ocugen has made amazing progress in executing against its objectives and continues to move diligently towards its pipeline milestones – factors that we feel will contribute significantly to their success," said Mr. Berik Kaniyev, Chairman of JSC Lancaster Group.